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Chronic hepatitis B, C, and D virus (HBV, HCV, and
HDV) infections are the leading causes of liver dis-
ease and cancer worldwide. Recently, the solute car-
rier and sodium taurocholate co-transporter NTCP
has been identified as a receptor for HBV and HDV.
Here, we uncover NTCP as a host factor regulating
HCV infection. Using gain- and loss-of-function
studies, we show that NTCP mediates HCV infection
of hepatocytes and is relevant for cell-to-cell
transmission. NTCP regulates HCV infection by aug-
menting the bile-acid-mediated repression of inter-
feron-stimulated genes (ISGs), including IFITM3. In
conclusion, our results uncover NTCP as a mediator
of innate antiviral immune responses in the liver, and
they establish a role for NTCP in the infection process
of multiple viruses via distinct mechanisms. Collec-
tively, our findings suggest a role for solute carriers
in the regulation of innate antiviral responses, and
they have potential implications for virus-host inter-
actions and antiviral therapies.
INTRODUCTION
Hepatitis B and C viruses (HBV and HCV) are the leading causes
of chronic liver disease worldwide (El-Serag, 2012). With 400Cell Rep
This is an open access article under the CC BY-Nmillion individuals chronically infected with HBV or HCV and at
risk for severe liver disease, these viruses are a major global
health burden (El-Serag, 2012; Wedemeyer et al., 2015).
Although HBV and HCV differ in their genomic organization
and life cycles, these viruses exclusively infect human hepato-
cytes (Baumert et al., 2014), suggesting that liver-specific factors
are important for the life cycle of both viruses.
Viral entry pathways contribute to HBV and HCV liver tropism.
HCV requires a number of host proteins, including cluster of dif-
ferentiation 81 (CD81), scavenger receptor BI (SR-BI), claudin-1
(CLDN1), occludin (OCLN), and accessory factors, such as
epidermal growth factor receptor (EGFR), to enter hepatocytes
(Baumert et al., 2014; Lupberger et al., 2011; Martin and Upri-
chard, 2013; Zeisel et al., 2013b; Zona et al., 2013). Some of
these host factors interact directly with HCV glycoproteins,
whereas others contribute to HCV internalization by promoting
co-receptor associations and inducing intracellular signaling
pathways (Kim et al., 2013; Lupberger et al., 2011). While key
host factors mediating HCV entry are well characterized (Zeisel
et al., 2013a), it is only partially understood how cell entry is regu-
lated. Furthermore, the role of innate immune responses target-
ing HCV entry is poorly understood.
The sodium taurocholate co-transporting polypeptide (NTCP),
a bile acid transporter expressed at the hepatocyte basolateral
membrane (Claro da Silva et al., 2013), was identified previously
as a receptor for HBV and hepatitis D virus (HDV) (Ni et al., 2014;
Yan et al., 2012). HDV can use HBV envelope proteins to
assemble infectious particles and is widely used as a surrogate
model to study HBV entry (Sureau, 2010). Exogenous NTCPorts 17, 1357–1368, October 25, 2016 ª 2016 The Author(s). 1357
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
expression in NTCP-lacking human hepatoma cell lines (such as
Huh7 and HepG2) renders these cells susceptible to HBV/HDV
entry (Ni et al., 2014; Yan et al., 2012). The natural ligands of
NTCP (i.e., conjugated and hydrophilic bile acids) compete
with HBV/HDV for NTCP binding and inhibit viral infection
(Yan et al., 2014). In contrast, bile acids have been shown to
enhance HCV replication (Chang and George, 2007; Chhatwal
et al., 2012), although the mechanisms are not yet defined.
Furthermore, whether bile acid transporters such as NTCP play
a role in infection of alternative hepatotropic viruses, such as
HCV, is unclear. In this study, we tested the role of NTCP
in HCV infection, and we identified the mechanisms by which a
solute carrier affects infectivity of three major hepatotropic
viruses.
RESULTS
NTCP Overexpression Enhances HCV Infection
To investigate the effect of NTCP expression on HCV infection,
we transduced the Huh7.5.1 cell line (Zhong et al., 2005) to ex-
press human NTCP. Huh7.5.1-NTCP cells expressed signifi-
cantly higher NTCP mRNA and protein levels (Figure 1A) and
surface levels of NTCP (Figure S1A) than parental Huh7.5.1 cells.
To confirm that NTCP is functional as a viral host factor in these
cells, Huh7.5.1-NTCP cells were infected with recombinant
HDV. Huh7.5.1-NTCP cells supported HDV infection, as demon-
strated by the presence of HDV RNA and delta antigen (HDAg)
7 days post-inoculation (Figure 1B). Moreover, HDV infection
was inhibited by the HBV preS1-derived peptide (Figure 1B),
which binds to NTCP and prevents HBV/HDV entry (Schieck
et al., 2013).
To assess if NTCP expression affects HCV infection, we used
cell culture-derived HCV (HCVcc) and lentiviral particles pseu-
dotyped with HCV E1E2 glycoproteins (HCVpp) of different ge-
notypes. Expression of NTCP significantly enhanced HCVcc
(Jc1 and JcR2A) infection and HCVpp (genotypes 1b, 2a, 3a,
and 4) entry compared to the parental cells (normalized as
100%) (Figures 1C and 1D). Interestingly, entry of vesicular sto-
matitis virus pseudoparticles (VSVpp) and murine leukemia
virus pseudoparticles (MLVpp) was not significantly affected
by NTCP expression under these conditions (Figure 1D). The
growth of Huh7.5.1 and Huh7.5.1-NTCP cells after seeding
was similar, indicating that our observations were unrelated
to effects on cell proliferation (Figure S1B). Furthermore, the
effect of NTCP on HCV entry/infection was independent of
the infectivity levels of different HCVpp and HCVcc strains (Fig-
ures S1C and S1D).
Since HCV can infect cells by direct cell-to-cell transmission
(Meredith et al., 2013; Timpe et al., 2008), we evaluated the
role of NTCP in this mode of viral dissemination. HCV-replicating
Huh7.5.1 cells were co-cultured with GFP-expressing Huh7.5
cells (Lupberger et al., 2011; Xiao et al., 2014) transduced or
not to express NTCP (Figure 1E). In this assay, the presence of
an anti-envelope E2 antibody inhibits cell-free infection, allowing
the specific assessment of cell-to-cell transmission. NTCP
expression significantly increased the percentage of GFP-posi-
tive HCV-infected cells, suggesting that NTCP also plays a role
in cell-to-cell spread (Figures 1F and 1G).1358 Cell Reports 17, 1357–1368, October 25, 2016Silencing NTCP Expression Inhibits HCV Infection
We confirmed the role of NTCP in HCV infection by silencing
NTCP expression in Huh7.5.1-NTCP cells using a small inter-
fering RNA (siRNA) targeting NTCP, prior to infection with
HCVcc. Following NTCP silencing in Huh7.5.1-NTCP cells, total
protein expression was decreased by 80%, which was re-
flected by decreased surface expression (Figure 2A). This corre-
sponded to a significant decrease in HCVcc infection (Figure 2B).
To rule out potential off-target effects, we tested multiple NTCP-
targeting small hairpin RNA (shRNA) sequences in Huh7.5.1-
NTCP cells. We confirmed that a decrease in NTCP expression
(by shNTCP2 and shNTCP3) (Figure 2C) correlated with a
decrease in HCVcc infection (Figure 2D). Furthermore, silencing
NTCP expression with shNTCP2 decreased protein expression
by >80% (Figure 2E), which significantly decreased entry of
HCVpp into Huh7.5.1-NTCP cells (Figure 2F), confirming the
relevance of NTCP for HCV entry.
NTCP Modulates HBV/HDV and HCV Infection via
Distinct Mechanisms
To assess whether NTCP interacts directly with HCV glycopro-
teins, we measured binding of recombinant soluble HCV E2
(sE2) to cells. We observed no significant difference in sE2 bind-
ing to NTCP-expressing or parental cells (Figure 3A). However,
sE2 treatment of Huh7.5.1 cells inhibited HCVcc infection (Fig-
ure 3B), confirming the functionality of the sE2 protein. These
findings indicate that NTCP is not involved in E2 binding. Further-
more, NTCP expression did not affect the expression of canon-
ical HCV entry factors in Huh7.5.1-NTCP cells compared to the
parental cells (Figure 3C).
We next tested the effect of the HBV preS1-derived peptide,
which is known to bind to NTCP and inhibit HBV/HDV entry (Ni
et al., 2014). Although preS1 inhibited HDV infection of Huh7.5.1-
NTCP cells after 1 hr pre-treatment, it had no effect on HCVpp
entry under these conditions (Figure 3D), indicating that the HBV
preS1-binding domain of NTCP is not required to promote HCV
entry.Wenext evaluatedwhether thebile acid transporter function
of NTCP is important for HCV entry. Huh7.5.1-NTCP cells were
treatedwith theHBVpreS1-derivedpeptide (Ko¨nig etal., 2014;Sli-
jepcevic et al., 2015), which inhibits bile acid uptake in vitro (IC50,
4 nM) (Ni et al., 2014), for 24, 48, and 72 hr prior to the addition
of HDV, HCVpp, or VSVpp (Figures 3E–3G). PreS1 treatment
(200 nM) significantly inhibited HCVpp entry in a time-dependent
manner, with a maximal inhibition of70% after 72 hr (Figure 3E).
Under these conditions, VSVpp entry also was reduced by preS1,
although to a lesser extent (Figure 3F), suggesting a general effect
on viral infection. In contrast, HDV infectionwas impairedbypreS1
regardless of the treatment duration (Figure 3G). HCVcc infection
alsowasdecreasedby72-hrpreS1 treatment (Figure3H), confirm-
ing that our observations are relevant for the infectious virus and
the full HCV life cycle. Taken together, our data suggest that
long-term preS1 inhibition of NTCP-mediated bile acid transport
perturbs cellular physiology to modulate HCV entry.
PreS1-Mediated Inhibition of NTCP Induces Interferon-
Stimulated Gene Expression
Since preS1 only affected HCV entry after long-term treatment
(Figure 3), we hypothesized that the bile acid transport activity
Figure 1. NTCP Expression Modulates HCV Infection
(A) NTCP expression in Huh7.5.1-NTCP cells compared to parental Huh7.5.1 cells evaluated by qRT-PCR and western blot. qRT-PCR results are expressed as
means ± SD. NTCP expression was normalized by GAPDH expression (log) from three independent experiments performed in triplicate (n = 9).
(B) Functional evaluation of HDV infection in Huh7.5.1-NTCP cells using northern blot and immunofluorescence (IF). Huh7.5.1 and Huh7.5.1-NTCP cells were
treatedwith anHBV-derived preS1 peptide (PreS1) or with a control peptide (Ctrl) (200 nM) and infectedwith recombinant HDV for 7 days. HDVRNAwas detected
by northern blot. HDV+ corresponds to23 107 HDV RNA genome equivalents extracted from HDV particles produced in Huh7 cells. NI, non-infected cells. One
experiment is shown. For IF analysis, cells were fixed 7 days after infection and stained with HDAg-specific antibodies purified from HBV/HDV co-infected
patients. HDV-positive cells are visualized in red. Cell nuclei were stained with DAPI (blue). One experiment is shown.
(CandD)HCVccandHCVpp infectionofNTCP-overexpressingcells.Huh7.5.1andHuh7.5.1-NTCPcellswere infectedwithHCVcc (C, Luc-Jc1andLuc-JcR2A;D,
HCVpp (genotypes 1b, 2a, 3a, and 4), VSVpp, andMLVpp). Infection was assessed after 72 hr bymeasuring luciferase activity. Results are expressed asmeans ±
SEMpercentage virus infection relative to parental Huh7.5.1 cells from three independent experiments (one performed in triplicate, one in quintuplicate, and one in
hextuplicate; n =14) (C) or three independent experiments performed in triplicate (n =9, exceptMLVpp: two independent experiments performed in triplicate, n = 6).
(E–G) NTCP overexpression increases HCV cell-to-cell transmission. HCV-electroporated Huh7.5.1 were transduced or not (Ctrl) with lentiviruses expressing
NTCP. (E) NTCP expression was assessed by qRT-PCR. Results are expressed as means ± SD relative NTCP expression (log) compared to NTCP expression in
non-transduced cells (set at 1) from one experiment performed in triplicate (n = 3). Cells were then co-cultured with GFP-expressing Huh7.5.1 cells in the
presence of neutralizing antibody AP33. (F and G) After NS5A staining, HCV cell-to-cell transmission was assessed by flow cytometry as the percentage of GFP-
and NS5A-positive cells. One experiment is shown (F) and results are expressed as means ± SD percentage infected cells from two independent experiments
(one performed in hextuplicate and one in nonuplicate; n = 15) (G).of NTCP inducesmetabolic or transcriptional changes that regu-
late virus infection. To test this hypothesis, we evaluated the ef-
fect of preS1-NTCP binding on gene expression in hepatoma
cells. We performed genome-wide microarray analyses of
Huh7.5.1-NTCP cells that were treated with preS1 or a scram-
bled peptide (200 nM) for 48 hr. Gene set enrichment analysis
(GSEA) indicated that preS1 treatment induces the expression
of genes involved in bile acid and fatty acid metabolism, as pre-
viously described (Oehler et al., 2014). Unexpectedly, preS1
treatment also induced the expression of genes involved ininnate immunity, such as IFNa responses and the Jak/Stat-
signaling pathway (Table 1; Figure 4A). Interestingly, IFITM2
and IFITM3, which encode two restriction factors targeting
HCV entry (Narayana et al., 2015), were among the preS1-
induced genes (Figure 4B).
To confirm that IFITMs function as restriction factors in
Huh7.5.1-NTCP cells, we exogenously overexpressed IFITM2
and IFITM3 (Figure 4C). Indeed, IFITM2 and IFITM3 overexpres-
sion inHuh7.5.1-NTCPcells inhibitedHCVcc infection (Figure4D).
However, as endogenous IFITM2 expression in Huh7.5.1 andCell Reports 17, 1357–1368, October 25, 2016 1359
Figure 2. Silencing NTCP Expression In-
hibits HCV Infection in Human Hepatocytes
(A and B) NTCP silencing in hepatoma cell lines.
Huh7.5.1-NTCP cells were transfected with siRNA
control (siCtrl) or siRNA targeting NTCP (siNTCP).
siRNA efficacy was assessed 72 hr after trans-
fection by western blot and IF (scale bar, 10 mm)
(A), and cell viability was assessed using
PrestoBlue reagent (B). 3 days after NTCP silen-
cing, Huh7.5.1-NTCP cells were infected with
HCVcc (Luc-Jc1). Infection was assessed after
72 hr by measuring luciferase activity. Results are
expressed as means ± SEM percentage cell
viability compared to cells treated with siCtrl from
three independent experiments (one performed in
sextuplicate and two performed in octuplicate;
n = 22) and means ± SEM percentage HCVcc
infection from four independent experiments per-
formed in quadruplicate (n = 16) (B).
(C–F) Effect of shNTCP silencing in hepatoma
cells. Huh7.5.1-NTCP cells were transduced with
lentiviruses expressing shRNAs targeting NTCP
(shNTCP1, shNTCP2, or shNTCP3) or control
shRNA (shCtrl). shRNA efficacy was assessed
72 hr after transduction by western blot (C) or
by western blot and IF (scale bar, 10 mm) (E).
Cell viability was assessed using PrestoBlue
reagent (D). Results are expressed as means ±
SEM percentage cell viability from three inde-
pendent experiments performed in octuplicate
(n = 24). 3 days after NTCP silencing, Huh7.5.1-
NTCP cells were infected with HCVcc (Luc-Jc1) (D
and F), HCVpp (genotype 1b) (F), or VSVpp (F).
Infection was assessed after 72 hr by measuring
luciferase activity. Results are expressed as
means ± SEM percentage HCVcc infection
from three independent experiments (two per-
formed in quadruplicate and one in sextuplicate;
n = 14) (D), or they are expressed as means ± SEM percentage pseudoparticle entry from three independent experiments performed in triplicate (n = 9) (F) and as
means ± SEM percentage HCVcc infection from three independent experiments performed in quadruplicate (n = 12) (F).Huh7.5.1-NTCP cells was low and at the limit of detection, we
focused on IFITM3 in further functional studies. Notably, IFITM3
expression was decreased at the protein level by 60% in
Huh7.5.1-NTCPcells compared to parental cells (Figure 4E), sug-
gesting that NTCPmodulates IFITM3 expression. To confirm that
thechanges ingeneexpressionweredirectly related toNTCPand
not to off-target effects of preS1, we selected IFITM3 and two
other genes involved in IFNa responses (PARP9 and CXCL10)
which were induced by preS1 treatment (Figure 4B), and we
compared their expression levels in Huh7.5.1 and Huh7.5.1-
NTCP cells. As expected, Huh7.5.1-NTCP cells had decreased
mRNA expression of IFITM3, PARP9, and CXCL10 compared
to parental cells (Figure 4F), confirming the specific role of
NTCP in the suppression of these genes. Thesedata support pre-
vious findings that preS1 binds with high specificity to NTCP
without off-target effects (Bogomolov et al., 2016).
Bile Acid Transport through NTCP Modulates the
Expression of Interferon-Stimulated Genes to Affect
HCV Infection
The gene expression analyses implied that NTCP facilitates HCV
entry by altering the expression of interferon-stimulated genes1360 Cell Reports 17, 1357–1368, October 25, 2016(ISGs). Given that the physiological function of NTCP is to trans-
port bile acids, and bile acids are known to affect ISG expression
in hepatocytes (Graf et al., 2010; Podevin et al., 1999), we hy-
pothesized that bile acid transport by NTCP regulates the
expression of ISGs and viral infection. Since IFITM3 functions
as an HCV restriction factor in our model system (Figure 4D),
we selected IFITM3 as a representative ISG for functional studies
to probe the link betweenNTCP and the IFN response. To ensure
that IFN responses are indeed functional in Huh7.5.1-NTCP
cells, we treated cells with Poly(I:C) and IFNa2, andwe evaluated
ISG induction by the expression of IFITM3. Poly(I:C) stimulation
of Huh7.5.1-NTCP cells significantly increased IFITM3 expres-
sion (Figure S2A). Moreover, STAT1 phosphorylation (Fig-
ure S2B) and IFITM3 mRNA expression (Figure S2C) were
markedly induced after IFNa2 treatment. This induction was
repressed by a specific antibody targeting the type I IFN receptor
(IFNAR) (Figures S2B and S2C).
We then evaluated the effect of NTCP on IFN responses in
these cells. The mere presence of NTCP decreased mRNA
expression of IFITM3 by 50% compared to parental cells (Fig-
ure 5A). The addition of bile acid (100 mMsodium taurocholate) to
Huh7.5.1-NTCP cells decreased IFITM3mRNA expression even
Figure 3. Distinct Roles of NTCP in HDV/HBV and HCV Infections
(A) Flow cytometry analysis of HCV glycoprotein sE2 binding to Huh7.5.1 (Ctrl) and Huh7.5.1-NTCP (NTCP). Results are expressed as means ± SD percentage
sE2 binding compared to control cells from three independent experiments (two performed in triplicate and one in quadruplicate; n = 10).
(B) sE2 binding inhibits HCVcc infection. Huh7.5.1 cells were treated with soluble sE2 and then infected with HCVcc (Luc-Jc1). Infection was assessed after 72 hr
by measuring luciferase activity. Results are expressed as means ± SD percentage HCVcc infection from three independent experiments performed in triplicate
(n = 9).
(C) Flow cytometry analysis of HCV entry factor expression in Huh7.5.1-NTCP cells. Results are expressed as percentage protein expression compared to
parental Huh7.5.1 cells (set at 100%) from four independent experiments performed in duplicate (n = 8).
(D) Effect of HBV preS1-derived peptide on HDV, HCVpp (genotype 1b), and VSVpp entry into Huh7.5.1-NTCP cells. Huh7.5.1-NTCP cells were treated for 1 hr
with preS1 or Ctrl peptide (200 nM). For HDV, cells were then infected with recombinant HDV for 7 days. Total RNA was purified and HDV RNA was detected by
qRT-PCR. Results are expressed as percentage HDV RNA level compared to non-treated Huh7.5.1-NTCP cells from three independent experiments performed
in triplicate (n = 9). For HCVpp (genotype 1b) and VSVpp, cells were infected with pseudoparticles and infection was assessed after 72 hr by luciferase activity.
Results are expressed as means ± SD percentage viral entry from three independent experiments performed in quintuplicate (n = 15).
(E–G) Time-dependent inhibition of viral entry by preS1 treatment. Cells were treated with preS1 or Ctrl peptide for 24, 48, and 72 hr prior to infection with HCVpp
(genotype 1b), VSVpp, or HDV. Infection was assessed as described above. (E) Results are expressed as means ± SD percentage HCVpp entry from five in-
dependent experiments performed in triplicate (n = 15). (F) Results are expressed as means ± SD percentage VSVpp entry from four independent experiments
performed in triplicate (n = 12). (G) Results are expressed as means ± SD percentage HDV infection from three independent experiments performed in duplicate
(n = 6).
(H) Treatment with preS1 inhibits HCVcc infection. Cells were treated with preS1 or Ctrl peptide for 72 hr prior to infection with HCVcc (Luc-Jc1). Infection was
assessed after 72 hr by measuring luciferase activity. Results are expressed as means ± SD HCVcc infection (relative light unit, RLU) from three independent
experiments performed in triplicate (n = 9).further, whereas blocking bile acid transport with the preS1 pep-
tide restored IFITM3mRNA expression to the levels observed in
Huh7.5.1 cells (Figure 5A). These findings suggest that the effect
of NTCP on ISG expression and HCV infection is dependent on
bile acid. Indeed, the addition of supplementary bile acid in the
cell culture medium dose-dependently increased HCVcc infec-
tion in Huh7.5.1-NTCP cells, but not in parental cells (Figure 5B).
We next evaluated the effect of preS1 treatment on IFITM3
protein expression and HCV infection in the presence of bile
acids. Reflecting our observations of the mRNA level (Figure 5A),
IFITM3 protein expression was decreased in Huh7.5.1-NTCP
cells compared toHuh7.5.1 cells in the presence of bile acid (Fig-ure 5C). However, treatment of Huh7.5.1-NTCP cells with preS1
(to block bile acid uptake) under these conditions induced a
2-fold increase in IFITM3 protein expression, effectively restoring
it to the level observed in Huh7.5.1 cells (Figure 5C). Further-
more, treatment of Huh7.5.1-NTCP cells with the preS1 peptide
in the presence of bile acid inhibited HCVcc infection (Figure 5D).
We did not observe these effects in Huh7.5.1 cells (Figures 5C
and 5D), confirming that the bile acid-mediated effect is depen-
dent on NTCP.
Interestingly, when we silenced IFITM3 expression (Figure 5E)
in the presence of bile acid, we observed an increase in
HCV infection (Figure 5F). However, this effect was no longerCell Reports 17, 1357–1368, October 25, 2016 1361
Table 1. Hallmark Gene Sets Significantly Induced, Positive
NESa, or Repressed, Negative NES, after preS1 Treatment in
Huh7.5.1-NTCP Cells Shown in Figure 4
Gene Set NESa p value FDRb
Bile acid metabolism 2.32 <0.001 <0.001
Coagulation 2.25 <0.001 <0.001
Xenobiotic metabolism 2.20 <0.001 <0.001
Fatty acid metabolism 2.20 <0.001 <0.001
Heme metabolism 2.04 <0.001 <0.001
Adipogenesis 1.91 <0.001 <0.001
Peroxisome 1.90 <0.001 <0.001
Interferon alpha response 1.90 <0.001 <0.001
Oxidative phosphorylation 1.90 <0.001 <0.001
Estrogen response late 1.89 <0.001 <0.001
Angiogenesis 1.72 0.002 0.003
Cholesterol homeostasis 1.68 0.004 0.005
Hypoxia 1.61 <0.001 0.010
Interferon gamma response 1.60 <0.001 0.009
Reactive oxygen species pathway 1.59 0.013 0.010
Estrogen response early 1.58 <0.001 0.011
Myogenesis 1.57 0.002 0.012
IL2 STAT5 signaling 1.54 <0.001 0.013
IL6 JAK STAT3 signaling 1.54 0.008 0.014
Complement 1.49 0.003 0.021
MTORC1 signaling 1.50 0.005 0.012
Unfolded protein response 1.82 <0.001 <0.001
G2M checkpoint 2.01 <0.001 <0.001
E2F targets 2.02 <0.001 <0.001
MYC targets V2 2.54 <0.001 <0.001
MYC targets V1 2.64 <0.001 <0.001
aNormalized enrichment score.
bFalse discovery rate.observed in the presence of preS1 to block bile acid uptake into
the cells or in the absence of bile acid (Figure 5F). These results
suggest that bile acid-mediated suppression of other ISGs
(which may otherwise compensate the absence of an individual
ISG) is necessary to observe a functional effect of IFITM3
silencing on HCV infection. Differences in bile acid levels in cell
culture medium also may explain why IFITM3 was not identified
as an HCV restriction factor in previous screens (Brass et al.,
2009).
NTCP-Mediated Bile Acid Transport Affects ISG
Expression and HCV Entry into Primary Human
Hepatocytes
For validation in a more physiological context, we investigated
the role of NTCP during HCV entry into primary human hepato-
cytes (PHHs). First, we silenced NTCP expression in PHHs us-
ing an NTCP-targeting siRNA. Following transfection of siNTCP,
the expression of NTCP protein was reduced by 50% (Fig-
ure 6A). The decrease in NTCP expression correlated with
a significant decrease in the entry of HCVpp genotype 1b
(Figure 6B).1362 Cell Reports 17, 1357–1368, October 25, 2016We next evaluated whether NTCP-mediated bile acid trans-
port affects ISG expression in PHHs. We treated PHHs with
bile acid in the presence or absence of preS1 and performed
genome-wide microarray analyses. GSEA showed that bile
acid treatment of PHHs suppressed the expression of genes
involved in the IFNa response (normalized enrichment score
[NES] 2.11; p value < 0.001; false discovery rate [FDR] <
0.001) (Figure 6C) as well as other immune-related pathways.
However, treatment of PHHs with preS1 under these conditions
induced the expression of genes involved in the IFNa response
(NES 1.5; p value = 0.014; FDR = 0.035) to restore their expres-
sion levels to normal conditions (i.e., PHHs in the absence of
bile acid) (Figure 6D). These findings are consistent with our
microarray analyses in Huh7.5.1-NTCP cells (Figure 4), where
expression of genes involved in IFNa responses was regulated
by treatment with preS1. Interestingly, IFITM1, IFITM2, and
IFITM3were among the genes suppressed by bile acid treatment
of PHHs (Figure 6C), and their expression could be rescued by
the addition of preS1 (Figure 6D). Moreover, the effects we
observed in PHHs were dependent on the presence of bile
acid, as treatment with preS1 in the absence of bile acid did
not have a major impact on the expression of these genes
(data not shown).
We next evaluated the functional effect of these changes
in ISG expression on HCVpp entry into PHHs. Treatment of
PHHs with bile acid increased HCVpp genotype 1b entry, and
the addition of preS1 under these conditions restored the level
of infection to that observed in the absence of bile acid (Fig-
ure 6E). Interestingly, the concentration of bile acid required to
see a robust effect for HCVpp entry into PHHs was higher than
for HCVcc infection of Huh7.5.1-NTCP cells (Figure 5B), which
may reflect different bile acid uptake efficiency in PHHs or that
the effect is more potent when the full HCV life cycle is measured
and ISGs targeting different steps of the viral infection cycle are
involved. Finally, to confirm that the activity of preS1 is linked to
IFN responses, we tested the effect of preS1 in the presence of
an antibody blocking the type I IFN receptor. In the presence of
this antibody, preS1 no longer inhibited HCVpp entry into PHHs
(Figure 6F), suggesting that the inhibitory effect of preS1 against
HCV entry is indeed mediated by the IFN signal transduction
cascade and resulting IFN responses in PHHs.
DISCUSSION
NTCP was recently described as a major receptor for HBV and
HDV entry. Here we show that NTCP also plays a role in HCV
infection. Exogenous expression of NTCP in Huh7.5.1 hepatoma
cells increased HCV infection, whereas silencing of NTCP
expression reduced HCV entry (Figures 1 and 2). Using microar-
ray analyses in cell lines (Figure 4) and PHHs (Figure 6), we
discovered that NTCP-mediated bile acid transport regulates
innate antiviral responses, thereby inhibiting HCV infection
and uncovering a role for NTCP as a regulator of antiviral
immunity.
Innate antiviral responses mediated by ISGs have been shown
to target multiple steps during viral infection, including entry (Liu
et al., 2011; Smith et al., 2014). IFITM1, IFITM2, and IFITM3,
which belong to a group of five IFN-induced transmembrane
Figure 4. Binding of HBV-Derived preS1 Pep-
tide to NTCP Increases ISG Expression
Huh7.5.1-NTCP cells were treated with preS1 or
control peptide for 48 hr. Cells were then lysed and
total RNA was extracted and purified. Total gene
expression was analyzed by genome-wide micro-
array. Three independent biological replicates per
condition from one experiment were analyzed.
(A) Schematic representation of Hallmark gene sets
that are significantly induced (red, including bile acid
metabolism and IFNa response) or repressed (blue)
following preS1 treatment, based on Table 1. p <
0.05 and FDR < 0.05 were considered statistically
significant.
(B) List of individual IFNa response genes that are
significantly (p < 0.05) overexpressed following
preS1 treatment. Individual Z scores for each
sample are presented. Negative Z score (blue) and
positive Z score (red) correspond to repression and
induction of the indicated genes, respectively.
(C and D) IFITM2 and IFITM3 overexpression inhibits
HCV infection. Huh7.5.1-NTCP cells were trans-
fected with an empty vector, pCMV-HA-hIFITM2, or
pCMV-HA-hIFITM3 for 3 days. (C) Expression of
transduced proteins as assessed by anti-HA west-
ern blot is shown. (D) Transduced cells were then
infected for 3 days with HCVcc (Luc-Jc1). Infection
was assessed after 72 hr by measuring luciferase
activity. Results are expressed as means ± SD
percentage HCVcc infection compared to control
cells (set at 100%) from three independent experi-
ments performed in triplicate (n = 9).
(E) IFITM3 protein expression in hepatoma cells.
IFITM3 protein expression was assessed bywestern
blot in Huh7.5.1 and Huh7.5.1-NTCP cells. One
experiment is shown.
(F) IFITM3, PARP9, and CXCL10 expression in
hepatoma cells. Basal expression of IFITM3,
PARP9, and CXCL10mRNA was quantified by qRT-
PCR in Huh7.5.1 and Huh7.5.1-NTCP cells. Results
are expressed as means ± SD percentage gene
expression compared to expression levels in
Huh7.5.1 cells (set at 100%) from three independent
experiments performed in triplicate (n = 9).proteins (Smith et al., 2014), have been shown to exert broad
antiviral activity against a range of viruses, including VSV, HIV,
dengue virus, influenza virus, and Zika virus (Savidis et al.,
2016; Smith et al., 2014). Interestingly, IFITM2 and IFITM3
were recently reported to restrict HCV infection at a late entry
step by targeting HCV for lysosomal degradation following endo-
cytosis (Narayana et al., 2015). IFITM1 was shown to interact
with HCV co-receptors at tight junctions to disrupt the HCV entry
process by alternative mechanisms (Wilkins et al., 2013).
Given that bile acids have been shown to modulate cellular
antiviral responses (Graf et al., 2010; Podevin et al., 1999), we hy-
pothesized that NTCP affects the induction of ISG expression via
its bile acid transport activity. Indeed, the expression of ISGs
(including IFITM1, IFITM2, and IFITM3) in PHHs was suppressed
by the addition of bile acid (Figure 6C). However, expression of
these ISGs in PHHs was restored by addition of the preS1 pep-
tide, which blocks NTCP-mediated bile acid uptake (Figure 6D).
Furthermore, modulation of the expression of IFITM3 by bile acid
or preS1 treatment had a clear functional effect on HCV infection(Figures 5 and 6). Our findings are consistent with a previous
report showing that bile acids affect HCV replication (Chhatwal
et al., 2012), probably by similar mechanisms as those we
describe here. In this study, we selected IFITM3 as a representa-
tive ISG for functional characterization, but the expression of
other ISGs is also affected by bile acids (Figure 6), likely contrib-
uting further to the overall effect on HCV infection. Since ISGs
broadly restrict viral infection, this is consistent with the time-
dependent effect of preS1 on VSVpp entry that we observed
(Figure 3).
Our data suggest that NTCP facilitates HCV infection by
modulating bile acid transport and ISG expression. ISGs also
restrict HCV cell-to-cell transmission (Meredith et al., 2014),
consistent with our finding that NTCP contributes to HCV cell-
to-cell spread (Figures 1E–1G). It should be noted that NTCP
expression did not appear to affect HCV entry in a recent Huh7
cell line model (Meredith et al., 2016). Huh7.5.1 cells are derived
from Huh7.5 cells, which differ from Huh7 cells by a single point
mutation in the retinoic acid-inducible gene-I (BartenschlagerCell Reports 17, 1357–1368, October 25, 2016 1363
Figure 5. Bile Acid Uptake Enhances HCV Infection by Decreasing ISG Expression
(A) The impact of bile acid and preS1 treatment on IFITM3 expression. Huh7.5.1-NTCP cells were treated with the bile acid (BA) sodium taurocholate (100 mM) or
with 200 nM preS1 for 72 hr. IFITM3 expression was then quantified by qRT-PCR. Results are expressed as means ± SD percentage IFITM3 expression
compared to untreated (Ctrl) Huh7.5.1-NTCP cells (set at 100%) from three independent experiments performed in duplicate (n = 6).
(B) The impact of bile acid on HCVcc infection. Huh7.5.1 and Huh7.5.1-NTCP cells were treated 0, 25, or 100 mM sodium taurocholate for 72 hr and then infected
with HCVcc (Luc-Jc1). Results are expressed as means ± SD percentage HCVcc infection compared to untreated (Ctrl) Huh7.5.1 and Huh7.5.1-NTCP cells (both
set at 100%) from three independent experiments performed in triplicate (n = 9).
(C and D) Effect of preS1-mediated inhibition of bile acid uptake on IFITM3 protein expression and HCVcc infection. Huh7.5.1 and Huh7.5.1-NTCP cells were
treated with sodium taurocholate (100 mM) in the presence or absence of preS1 peptide for 72 hr. (C) IFITM3 protein expression was assessed by western blot.
One experiment is shown. (D) Cells were then infected byHCVcc (Jc1) for 3 days. Results are expressed asmeans ±SD percentage HCVcc infection compared to
Huh7.5.1 and Huh7.5.1-NTCP cells treated with control peptide (both set at 100%) from three independent experiments performed in triplicate (n = 9).
(E and F) Silencing of IFITM3 expression increases HCV infection in a bile acid-dependent manner. Huh7.5.1-NTCP cells were transfected with siRNA control
(siCtrl) or siRNA targeting IFITM3 (siIFITM3) and then treated for 72 hr in the absence or presence of BA (100 mM) in the presence of either preS1 or Ctrl peptide
(200 nM). (E) Then 3 days after transfection, silencing efficacy was assessed by measuring expression of IFITM3mRNA by qRT-PCR. Results are expressed as
means ± SD percentage IFITM expression from four independent experiments performed in triplicate (n = 12). (F) Cells were then infected with HCVcc Luc-Jc1.
Infection was assessed after 72 hr by measuring luciferase activity. Results are expressed as means ± SD percentage HCVcc infection compared to cells treated
with siCtrl (set at 100% for each condition) from four independent experiments performed in triplicate (n = 12).and Pietschmann, 2005; Zhong et al., 2005). Thismay explain the
differences observed between the two cell lines. Moreover, dif-
ferences in bile acid concentrations in cell culture medium may
be responsible for differences in the effect of NTCP on cell entry
of HCV (Figure 5C). However, our loss-of-function studies and
microarray analyses in PHHs (Figure 6) clearly demonstrate
the impact of NTCP on HCV infection in primary cells with phys-
iological innate immune responses.
For HBV/HDV infection, viral entry requires direct interaction
with NTCP (Ni et al., 2014; Yan et al., 2012). Furthermore, HBV
binding to NTCP may interfere with the physiological function
of NTCP (i.e., bile acid uptake), and NTCP ligands can abrogate
HBV/HDV infection (Oehler et al., 2014; Yan et al., 2014). In1364 Cell Reports 17, 1357–1368, October 25, 2016contrast, NTCP modulates HCV entry independently of direct
binding mechanisms. We confirmed the inhibitory effect of
the HBV preS1-derived peptide on HDV infection following 1-hr
treatment (Figure 3D), but we did not see a corresponding effect
on HCV infection under these conditions. Furthermore, the effect
of NTCP on HCV infection does not appear to involve HCV E2 or
binding factors CD81 and SR-BI (Pileri et al., 1998; Scarselli
et al., 2002) (Figures 3A and 3B). NTCP expression did notmodu-
late the expression of canonical entry factors CLDN1 and OCLN
or EGFR either (Figure 3C).
Other mechanisms may contribute to the effects of NTCP on
viral entry and infection that we observed. Indeed, modulation
of NTCP bile acid transport activity by preS1 affected IFN
Figure 6. NTCP-Mediated Bile Acid Uptake
Modulates ISG Expression and HCV Entry
in PHHs
(A and B) Silencing NTCP expression in PHHs.
PHHs were transfected with siRNA control (siCtrl)
or siRNA targeting NTCP (siNTCP). 3 days after
transfection, siRNA efficacy was assessed by
western blot (A), and cell viability was assessed
using PrestoBlue reagent (B). Results are ex-
pressed as means ± SEM percentage cell viability
compared to cells treated with siCtrl from two
independent experiments performed in quintu-
plicate (n = 10) (B). 3 days after NTCP silencing,
PHHs were incubated with HCVpp (genotype 1b).
Infection was assessed after 72 hr by measuring
luciferase activity. Results are expressed as
means ± SEM percentage HCVpp entry from
three independent experiments performed in
triplicate (n = 9) (B).
(C and D) Bile acids modulate the expression of
ISGs in PHHs. PHHs from a single donor were
treated with the bile acid (BA) sodium taur-
ocholate (500 mM) in the presence or absence of
the preS1 peptide (400 nM) for 48 hr. Cells were
then lysed and total RNA was extracted and pu-
rified. Total gene expression was analyzed by
genome-wide microarray. Three independent
biological replicates per condition were analyzed.
(C) Individual IFNa response genes that are
significantly (p < 0.05) repressed following BA
treatment are shown. Individual Z scores for each
sample are presented. Negative Z score (blue)
and positive Z score (red) correspond to repres-
sion and induction of the indicated genes,
respectively. (D) Effect of preS1 treatment on the
expression of IFNa response genes presented in
(C). Individual Z scores for each sample are
presented.
(E) Effect of bile acid and preS1 treatment on
HCVpp infection in PHHs. PHHswere treated with
increasing concentrations (0, 100, and 500 mM) of
BA in the presence of either preS1 or Ctrl peptide
(400 nM) for 72 hr and then infected with HCVpp
(genotype 1b). Infection was assessed after 72 hr
by measuring luciferase activity. Results are expressed as means ± SEM percentage HCVpp entry compared to untreated PHHs in the presence of the control
peptide (set at 100%) from four independent experiments performed in triplicate (n = 12).
(F) PreS1 inhibition of HCVpp entry is dependent on the IFN-signaling pathway in PHHs. PHHs were treated with 500 mM BA in the presence of preS1 or a
scrambled control peptide (400 nM), with or without treatment with an antibody targeting the type I IFN receptor (IFNAR) for 72 hr. Cells were then infected with
HCVpp (genotype 1b) and infection was assessed after 72 hr by measuring luciferase activity. Results are expressed as means ± SEM percentage HCVpp entry
compared to PHHs treated with the control peptide and an IgG control (set at 100%) from three independent experiments (one performed in triplicate and two in
quintuplicate; n = 13).responses, but also bile acid metabolism and cholesterol ho-
meostasis in Huh7.5.1-NTCP cells as well as other pathways
(Table 1). In particular, modulation of bile acid metabolism and
cholesterol homeostasis by preS1 would alter cellular choles-
terol pools, which has been shown to affect the activation of
type I IFN responses (York et al., 2015) and may potentially
contribute to the effect on HCV infection that we observed.
Furthermore, modulation of signaling and transcription factor
targets (Table 1) may have additional effects on viral replication
and translation.
Our results demonstrate that NTCP, acting by distinct mecha-
nisms, is relevant for the three major viruses causing chronichepatitis and liver disease. This finding could contribute to the
development of antiviral strategies targeting NTCP. Targeting
viral cell entry with receptor antagonists, antibodies, peptides,
and receptor kinase inhibitors has provided perspectives to pre-
vent and treat chronic hepatitis B and C infections (Colpitts et al.,
2015). Myrcludex B, a preS1-derived peptide targeting NTCP (Ni
et al., 2014; Volz et al., 2013), has been shown to protect against
HBV infection (Petersen et al., 2008), to modulate viral spread in
animal models (Volz et al., 2013), and to decrease HDV viral load
in patients in a phase II clinical trial (Bogomolov et al., 2016). Here
we show that preS1-NTCP binding enhances the expression of
ISGs. These data suggest that myrcludex B may inhibit HBVCell Reports 17, 1357–1368, October 25, 2016 1365
infection by a dual mode of action, by interfering with viral bind-
ing and potentially increasing ISG expression. NTCP-targeting
agents in clinical development also may inhibit HCV infection,
which is of interest particularly for patients with HBV/HDV/HCV
co-infections.
NTCP is a member of the solute carrier (SLC) family of
proteins, a group of membrane proteins having crucial roles
in many physiological functions (Ce´sar-Razquin et al., 2015).
However, these proteins are relatively uncharacterized. Here
we uncover NTCP as a mediator of innate antiviral responses
in hepatocytes and establish a role for NTCP in the entry pro-
cess of multiple viruses. Our data uncover an important role of
SLCs in virus-host interactions by linking their function to the
regulation of innate immune responses. Moreover, bile acid
transport through SLCs profoundly affects liver gene expression
(Table 1).
Overall, we have identified NTCP as a regulator of innate im-
mune responses in the human liver. These findings improve the
understanding of virus-host interactions in the human liver, and
they may open perspectives for the development of broad anti-
viral therapies targeting hepatotropic viruses that cause chronic
liver disease and cancer.
EXPERIMENTAL PROCEDURES
Cell Lines
The sources for 293T and Huh7.5.1 cells have been described (Lupberger
et al., 2011). Huh7.5.1 cells were seeded in six-well plates at 50% conflu-
ency 1 day prior to transduction with human NTCP-expressing VSVpp
(GeneCopoeia). Cells were incubated in DMEM (Gibco) containing 10% fetal
bovine serum (Dutscher). After 3 days, the cells were expanded and selected
for NTCP expression with 1.8 mg/mL puromycin.
PHHs
Liver tissue from patients undergoing surgical resection was obtained with
informed consent from all patients. The respective protocols were approved
by the Ethics Committee of the University of Strasbourg Hospitals (CPP 10-
17). PHHs were isolated from liver resection tissue and cultured in William’s
E medium (Sigma) (Krieger et al., 2010; Lupberger et al., 2011).
Viral Infection
Lentiviral pseudoparticles expressing HCV envelope glycoproteins (HCVpp
strains HCV-J [1b], JFH1 [2a], NIH S52 [3a], and UKN4.21.16 [4]), VSVpp,
MLVpp, as well as cell culture-derived HCVcc (Luc-Jc1 and Luc-JcR2A)
were generated as described (Fofana et al., 2010; Lupberger et al., 2011).
Huh7.5.1 cells and PHHswere infected as described (Krieger et al., 2010; Lup-
berger et al., 2011). Pseudoparticle entry and HCVcc infection were assessed
by measuring luciferase activity 72 hr post-infection (Krieger et al., 2010; Lup-
berger et al., 2011). HDV production and infection have been described (Verrier
et al., 2016) (see the Supplemental Experimental Procedures).
Gene Expression Analyses in Huh7.5.1-NTCP Cells and PHHs
Treated with Bile Acids and preS1 Peptide
Huh7.5.1-NTCP cells were treated with preS1 or a control peptide
(200 nM) for 48 hr. Alternatively, PHHs were treated with bile acids (500 mM)
in presence of preS1 or a control peptide (400 nM) for 48 hr. Total
RNA from three biological replicates per condition from one experiment was
then extracted using the ReliaPrep Kit (Promega), and 200 ng was
subjected to genome-wide transcriptome profiling using HumanHT-12
beadarray (Illumina), following the manufacturer’s protocol. Raw scanned
data were normalized by cubic spline algorithm using Illumina normal-
izer module of GenePattern genomic analysis toolkit (http://software.
broadinstitute.org/cancer/software/genepattern), as previously described1366 Cell Reports 17, 1357–1368, October 25, 2016(Hoshida et al., 2008). Modulated molecular pathways were determined using
GSEA (Subramanian et al., 2005).
Statistical Analysis
Each experiment was performed at least two times in an independent manner.
The number of independent experiments as well as the total number of biolog-
ical replicates (n) are indicated in the figure legends. Statistical analyses were
performed usingMann-Whitney U test by comparing values from every biolog-
ical replicate per study (indicated by ‘‘n’’ in the figure legends); p < 0.05 (*), p <
0.01 (**), and p < 0.001 (***) were considered statistically significant. Significant
p values are indicated by asterisks in the individual figures. For microarray an-
alyses, two-tailed unpaired Student’s t test was performed by comparing the
values from three biological replicates (p < 0.05 was considered statistically
significant).
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Figure S1. NTCP modulates HCV infection, related to Figure 1. A. Immunodetection of NTCP expression in 
Huh7.5.1 and Huh7.5.1-NTCP cells. Huh7.5.1 and Huh7.5.1-NTCP cells were treated with AF647-labelled preS1 
peptide. One experiment is shown. Scale bar, 10 m. NTCP protein was visualized in red after AF647-preS1 
binding and cell nuclei were stained with DAPI (blue) B. Comparable cell growth between Huh7.5.1 and Huh7.5.1-
NTCP cells. Huh7.5.1 and Huh7.5.1-NTCP cells were plated and cell growth was assessed every 24 h for 3 days 
by counting using an automated cell counter. Results are expressed as means ± SD cell counts from three 
independent experiments performed in triplicate (n=9). C-E. HCVpp, VSVpp, MLVpp, and HCVcc infection of 
NTCP-overexpressing cells. Huh7.5.1 and Huh7.5.1-NTCP cells were infected with HCVpp (genotypes 1b, 2a, 3a 
and 4, C), VSVpp and MLVpp (D), or HCVcc (Luc-Jc1 and JcR2A, E). Infection was assessed after 72 h by 
measuring luciferase activity. Results are expressed as means ± SD log relative light units (RLU) from one 
representative experiment performed in triplicate (n=3). 
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Figure S2. Expression and induction of ISGs in hepatoma cells, related to Figure 5. A. IFITM3 expression is 
induced by Poly(I:C) in Huh7.5.1-NTCP cells. Huh7.5.1-NTCP cells were reverse-transfected with Poly(I:C) (1 
µM/mL) for 24 h. IFITM3 expression was then assessed by qRT-PCR. Results are expressed as means ± SEM 
relative IFITM3 expression (fold change) compared to IFITM3 expression in non-transfected cells (set at 1) from 
three independent experiments performed in triplicate (n=9). B-C. IFITM3 expression is induced by type I IFN 
treatment in a STAT1-dependent manner in Huh7.5.1-NTCP cells. Huh7.5.1-NTCP cells were treated with IFNα2 
(1,000 UI/mL) in the presence or absence of a specific anti-IFNAR antibody. After 10 minutes of IFNα2 treatment, 
cells were lysed and STAT1 as well as phospho-STAT1 (pSTAT1) expression was assessed by Western blot (B). 
One experiment is shown. C. After 24 h of IFNα2 treatment, cells were lysed and IFITM3 expression was assessed 
by qRT-PCR. Results are expressed as means ± SD relative IFITM3 expression (fold change) compared to control 
cells (set at 1) from three independent experiments performed in triplicate (n=9).  
 
 
 
Supplemental Experimental Procedures 
 
Detection of NTCP protein by Western blot and immunofluoresence. Immunoblots of cell lysates using 
protein-specific antibodies (a rabbit anti-NTCP polyclonal antibody [Sigma, HPA042727] and a mouse anti-β-
actin monoclonal antibody [Sigma, A5441]) were performed in parallel as described (Verrier et al., 2016). Cell 
lysates were pre-treated with peptide-N-glycosidase (PNGase, NEB) following the manufacturer’s instructions. 
Quantification of protein expression was performed using ImageJ software. For detection of NTCP protein by 
immunofluorescence, a myristoylated peptide derived from the preS1 domain of the large HBV envelope protein 
labeled with Alexa Fluor 647 (AF647) fluorophore (Bachem, Switzerland) was used as described (Verrier et al., 
2016). Briefly, cells were treated with the AF647-preS1 peptide at 4°C for two hours and then fixed with 4% 
paraformaldehyde. Nuclei were stained with DAPI. The preS1 peptide specifically binds to NTCP and its primary 
structure has been described elsewhere (Schieck et al., 2013; Yan et al., 2012). Fluorescent imaging was performed 
using an Axio Observer Z1 microscope (Carl Zeiss, Germany). 
 
Cell viability assays and quantification of cell proliferation. Cell viability was assessed using PrestoBlue® Cell 
Viability Reagent (Fisher) as described (Verrier et al., 2016). Cell viability was assessed by measuring absorbance 
at 560 nm. For quantification of cell proliferation, Huh7.5.1 and Huh7.5.1-NTCP cells were seeded in 24 well 
plates for three days. Every 24 h, cell growth was assessed by counting cells using a TC20™ Automated Cell 
Counter (Bio-Rad). 
 
Quantification of gene and protein expression. Total RNA was extracted from cells using the RNeasy Mini Kit 
(Qiagen) or ReliaPrep Kit (Promega). cDNA was reverse-transcribed from total RNA using Maxima reverse 
transcriptase (Thermo Scientific). qPCR was performed using a CFX96 thermocycler (Bio-Rad) according to the 
Supplemental Information  
3 
 
manufacturer’s instructions. Primers and TaqMan® probe for GAPDH, SLC10A1 (NTCP), IFITM2, IFITM3, 
PARP9, and CXCL10 mRNA detection were obtained from ThermoFisher (TaqMan® Gene Expression Assays). 
All values were normalized to GAPDH expression. IFITM3 protein expression was assessed by Western blot. 
Immunoblots of cell lysates using protein–specific antibodies (a rabbit anti-IFITM3 monoclonal antibody [Abcam, 
ab109429] and a mouse anti-β-actin monoclonal antibody [Sigma, A5441]) were performed as described (Verrier 
et al., 2016). Quantification of protein expression was performed using ImageJ software.  
 
HCV cell-to-cell transmission assay. The HCV cell-to-cell transmission assay has been described previously 
(Xiao et al., 2014). Briefly, producer Huh7.5.1 cells were electroporated with HCV Jc1 RNA. GFP-overexpressing 
Huh7.5 cells (Xiao et al., 2014) were transduced or not with human NTCP-expressing VSVpp (GeneCopoeia). 
HCV-replicating Huh7.5.1 cells were then co-cultured with uninfected target Huh7.5-GFP or Huh7.5-GFP-NTCP 
cells in the presence of neutralizing antibody AP33 (25 µg/mL) to inhibit cell-free entry. After co-culture for 24 
h, cells were fixed with 1% paraformaldehyde (PFA), stained with an NS5A-specific mouse antibody (0.1 mg/mL) 
and analyzed by flow cytometry as described (Xiao et al., 2014). Cell-to-cell transmission was defined as 
percentage HCV infection of Huh7.5-GFP target cells.  
 
siRNAs and shRNA expression plasmids for perturbation studies. One siRNA pool (Qiagen GeneSolution 
siRNA GS6554) targeting NTCP or one non-targeting siRNA control (Qiagen) were reverse transfected into PHH 
and Huh7.5.1-NTCP cells with Lipofectamine® RNAiMAX (Invitrogen) as described (Lupberger et al., 2011). 
Three unique 29mer NTCP-targeting shRNA constructs in lentiviral GFP vector (pGFP-C-shLenti plasmid) 
expressing shNTCP #1 (ref TL309420A, 5’ CCT CAG CAT TGT GAT GAC CAC CTG CTC CA 3’), shNTCP 
#2 (ref TL309420B, 5’ CAT GGA GTT CAG CAA GAT CAA GGC TCA CT 3’), and shNTCP #3 (ref 
TL309420C, 5’ CCA ACT CTG TTC CAC CAT CCT CAA TGT GG 3’) were used to transduce cells for 72 h 
(ORIgene). A non-targeting shRNA sequence (shCTRL - ref TR30021, non-effective scrambled pGFP-lenti) was 
used as a control. One siRNA pool (SMARTpool ON-TARGETplus, Dharmacon) targeting IFITM3 or one siRNA 
control (Dharmacon) were reverse transfected into Huh7.5.1-NTCP cells with Lipofectamine® RNAiMAX 
(Invitrogen) as described (Lupberger et al., 2011). 
 
HCV entry factor expression. HCV entry factor expression was assessed by flow cytometry using antibodies 
targeting CD81 (QV6A8F2C4) (Fofana et al., 2013), SR-BI (QQ4G9A6) (Zahid et al., 2013), CLDN1 
(OM7D3B3) (Fofana et al., 2010), OCLN (Invitrogen), or EGFR (Santa Cruz Biotechnologies) (Barth et al., 2008; 
Lupberger et al., 2011). The antibodies targeting CD81, SR-BI, CLDN1, and EGFR were used without cell 
permeabilization to allow cell surface protein quantification. For detection of NTCP protein, a myristoylated 
peptide derived from the preS1 domain of the large HBV envelope protein labeled with Alexa Fluor 647 
fluorophore (Bachem, Switzerland) was used (Verrier et al., 2016). Cells were treated with the peptide for 1 h at 
37°C and then fixed with 4% PFA. NTCP expression was then quantified by flow cytometry. 
 
Cellular HCV E2 binding. The sE2 binding experiment was performed as described (Krieger et al., 2010; Zahid 
et al., 2013). Cells were incubated with His-tagged sE2 for 1 h and sE2 binding was quantified by flow cytometry 
using a RGS-His antibody (Qiagen).  
 
Overexpression of IFITM2 and IFITM3 in Huh7.5.1-NTCP cells. Huh7.5.1-NTCP cells were seeded at 50% 
confluency 24 h prior to transfection with an empty vector, pCMV-HA-hIFITM2 (Addgene #58398), or pCMV-
HA-hIFITM3 (Addgene #58397) (Yount et al., 2010) using FuGENE® HD Transfection Reagent (Promega). 
Protein expression was assessed by Western blot using a mouse anti-HA tag monoclonal antibody (Abcam 
ab18181) 72 h after transfection. Cells were then infected with HCVcc (Luc-Jc1) for 3 days and infection was 
assessed as described. 
 
Stimulation of ISG expression in Huh7.5.1-NTCP cells. For Western blot analysis of STAT1 and pSTAT1 
expression, Huh7.5.1-NTCP cells were incubated with a mouse monoclonal antibody targeting the type I IFN 
receptor (IFNAR) (Millipore MAB1155) or a mouse control IgG (Invitrogen) at 2.5 µg/mL for one hour before 
treatment with recombinant IFNα2a (BioVision) at 1,000 UI/mL. Following 10 minutes of IFNα2a treatment, cells 
were lysed and STAT1 and pSTAT1 expression were assessed by Western blot using rabbit specific antibodies 
(Cell signaling #9172 and #9167, respectively) following manufacturer’s instructions. For IFITM3 expression 
after IFNα2a stimulation, Huh7.5.1-NTCP cells were co-incubated for 24 h with a mouse monoclonal antibody 
targeting IFNAR or a mouse control IgG at 2.5 µg/mL and IFNα2a at 1,000 UI/mL. IFITM3 gene expression was 
then assessed by qRT-PCR. For Poly(I:C) stimulation, Poly(I:C) (Sigma) (1µg/mL) was reverse transfected into 
Huh7.5.1-NTCP cells with Lipofectamine® RNAiMAX (Invitrogen). IFITM3 gene expression was assessed by 
qRT-PCR 24 h after transfection. 
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Investigation of the effects of bile acid on viral infection and IFITM3 expression. Huh7.5.1 or Huh7.5.1-NTCP 
cells were incubated for 72 h with the bile acid sodium taurocholate (25 µM and 100 µM) (Sigma) and/or the 
preS1 peptide (200 nM) or a scrambled peptide control (200 nM). Total RNA was then extracted, and IFITM3 
expression was assessed by qPCR as described above, or cells were lysed and IFITM3 protein expression was 
assessed as described above. Alternatively, treated cells were infected with HCVcc (Luc-Jc1) for 72 h. PHHs were 
cultured in serum-free medium (i.e. containing no bile acids) and treated for 72 h with increasing concentrations 
(100 M and 500 µM) of sodium taurocholate in the presence of the preS1 peptide or a control peptide (400 nM) 
and then infected with HCVpp (genotype 1b) for 72 h. Viral entry was assessed by measuring luciferase activity. 
 
IFN signal transduction and HCV infection. PHHs were treated for 72 h with 500 µM of sodium taurocholate 
in the presence of the preS1 peptide or a control peptide (400 nM), in the presence of a mouse monoclonal antibody 
targeting the type I IFN receptor (IFNAR) (Millipore MAB1155) or a mouse control IgG (Invitrogen) at 2.5 µg/mL 
and then infected with HCVpp (genotype 1b) for 72 h. Viral entry was assessed by measuring luciferase activity. 
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